AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01557504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo to fixed dose combination tablet of sitagliptin and metformin. Matching placebo tablets are same size, shape and color as the active product, but do not contain any markings.
Study NCT01557504 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Concomitant use of metformin is permitted during the study provided the participant has been receiving a stable metformin dose for at least 12 weeks prior to the dose of study drug. Administration of metformin will be withheld for 24 hours prior to study drug administration and for 24 hours postdose.
Study NCT03823677 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypoxia
Description: hypoxia
Study NCT01557504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Concomitant use of metformin is permitted during the study provided the participant has been receiving a stable metformin dose for at least 12 weeks prior to the dose of study drug. Administration of metformin will be withheld for 24 hours prior to study drug administration and for 24 hours postdose.
Study NCT01557504 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Thyroid hormone
Description: Concomitant use of thyroid hormone (eg, levothyroxine) is permitted during the study provided the participant has been receiving a stable dose for at least 12 weeks prior to study drug administration and is euthyroid as documented by thyroid stimulating hormone testing at prestudy. Administration of thyroid hormone will be withheld for 24 hours prior to study drug administration and for 24 hours postdose.
Study NCT01557504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thyroid hormone
Description: Concomitant use of thyroid hormone (eg, levothyroxine) is permitted during the study provided the participant has been receiving a stable dose for at least 12 weeks prior to study drug administration and is euthyroid as documented by thyroid stimulating hormone testing at prestudy. Administration of thyroid hormone will be withheld for 24 hours prior to study drug administration and for 24 hours postdose.
Study NCT00869102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLP-1
Description: intravenous, 124,5 pmol/kg body weight
Study NCT03170362 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacogenetic Test
Description: The intervention is a battery of pharmacogenetic test results that mostly affect the metabolism of antidepressants and other medications.
Study NCT00299325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimonabant
Description: Tablet, oral administration
Study NCT00299325 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Rimonabant)
Description: Tablet, oral administration
Study NCT01337609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganeden BC30
Description: 2 billion CFU per capsule; One pill daily for 60 days
Study NCT01337609 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (sugar pill)
Description: 1 pill daily for 60 days
Study NCT00299325 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Mild hypocaloric diet
Description: Calculated by the dietitian based on the estimated basal metabolism rate and the physical activity
Study NCT00299325 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mild hypocaloric diet
Description: Calculated by the dietitian based on the estimated basal metabolism rate and the physical activity
Study NCT04171700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: Oral rucaparib will be administered twice daily. The starting dose will be 600 mg daily (BID).
Study NCT01462994 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Blood will be withdrawn at baseline and in intervals of 3 months for a total period of 2 years
Study NCT01134900 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacy Dashboard Review and Intervention
Description: Clinical pharmacist reviews patients on dashboard and makes intervention with providing team when necessary.
Study NCT04320069 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Omnipod Horizon™ Automated Glucose Control System
Description: Omnipod Horizon™ Automated Glucose Control System use in Manual Mode
Study NCT04081207 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AAC for Language Recovery (AAC-LaRc)
Description: iPads will be programmed with a personalized communication application (app) and a structured 4-step intervention will be employed to instruct patients how to cue themselves during anomic events via pictures, text, or speak buttons.
Study NCT03791125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salvianolic Acid A
Description: 4 anticipated doses are 30 mg, 90 mg, 180 mg and 270 mg, respectively. All of these are single-dose study.
Study NCT03791125 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo tablets containing no salvianolic acid A will be given to healthy subjects.
Study NCT02811029 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: measurement of phonology
Description: measurement of phonology will be assess using BILO-3, EDA, VS and VL tests
Study NCT02084953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-791325
Study NCT02084953 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Study NCT02084953 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching BMS-791325
Study NCT01865591 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound-based Renal Denervation
Study NCT04898608 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intradialytic Exercise
Description: Participants will do concurrent exercise (a combination of aerobic exercise and resistance training) for 30-60 minutes during the second hour of their routine hemodialysis sessions.~To determine the intensity of the prescribed exercise, maximum heart rate is used for aerobic workout and 1RM for resistance protocols.~Exercises will be performed at a moderate exercise intensity (12-14 on the Borg RPE Scale).~All protocols are tailor-made based on each individual's needs and physical abilities.
Study NCT03939286 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Clinical-neurological and neuropsychological tests
Description: The tests include established standardized questionnaires and detailed clinical neuropsychological examinations (e.g., tests on cognition and perception). In order to avoid exercise effects in multiple examinations, so-called parallel procedures should be used.
Study NCT01337609 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Ganeden BC30, Placebo (sugar pill)
Description: Ganeden BC30 (2 billion CFU per capsule), One capsule daily for 30 days Sugar Pill (placebo), One capsule daily for 30 days
Study NCT03939286 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Blood sampling
Description: Venous blood sampling (40 ml) is performed according to the usual criteria of sterile working at baseline and after intervention.
Study NCT03939286 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Assessment of physical activity via fitness tracker/diary
Description: All study participants, regardless of group classification, are randomly selected for a period of one week using Fitbit Charge 2® fitness trackers. The study participants are asked in this context to pursue their regular activity and to wear the bracelets for a week throughout. All study participants are asked to document their activities in a hand-written diary.
Study NCT03939286 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: MRI-examinations
Description: Standard MRI-methods, Sodium MRI, Phosphor MRS, Wholebody-Fat-MRI
Study NCT04071938 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Teaching to GPs
Description: Educational modules on bladder, bowel and skin-care, and pain management will be provided to participating GPs by Spinal Cord Injury specialists
Study NCT04071938 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Site visits to GP practices
Description: Visits by specialized nurses to the participating GPs at their practices to support the establishment of specialized care on-site
Study NCT00599326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferasirox
Description: 250 mg of deferasirox once daily for 6 months
Study NCT01101737 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nurse-led blood pressure clinic
Description: Blood pressure will be measured according to protocol.For patients with blood pressure above optimal targets, treatment changes will be discussed with the patient, a visiting consultant physician and the patient's GP. If they agree, the GP will intensify anti-hypertensive treatment with monthly follow up by the specialist nurse until BP targets are achieved.
Study NCT02419040 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Barbotage
Description: A 18-gauge needle connected to a 5 ml syringe with 4 ml of saline solution will be used to puncture the calcification with freehand technique and under constant sonographic monitoring. With the tip of the needle placed in the center of the deposit, the calcification will be flushed. Finally, a new 21-gauge needle will be introduced into the subacromial-subdeltoid bursa and 9 ml of 1% Lidocain hydrochlorid and 1 ml (20 mg) of Triamcinolon will be injected into the subacromial-subdeltoid bursa. All patients will be instructed by a physioteherapist in home exercises.
Study NCT02419040 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid injection
Description: The tip of the 18-gauge needle will be placed in the soft parts outside of the rotator cuff and movements mimicking the lavage procedure will be performed. A lavage procedure usually takes 5 minutes and the same period of time will have to be used for the mimicking maneuver. Finally, a new 21-gauge needle will be introduced into the subacromial-subdeltoid bursa and 9 ml of 1% Lidocain hydrochlorid and 1 ml (20 mg) of Triamcinolon will be injected into the subacromial-subdeltoid bursa. All patients will be instructed by a physioteherapist in home exercises.
Study NCT02419040 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Lidocain injection (sham)
Description: The tip of the 18-gauge needle will be placed in the soft parts outside of the rotator cuff and movements mimicking the lavage procedure will be performed. A lavage procedure usually takes 5 minutes and the same period of time will have to be used for the mimicking maneuver. Finally, a new 21-gauge needle will be introduced into the subacromial-subdeltoid bursa and 10 ml of 1% Lidocain hydrochlorid will be injected into the subacromial-subdeltoid bursa. All patients will be instructed by a physioteherapist in home exercises.
Study NCT04394052 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MR imaging
Description: Medical imaging
Study NCT00550420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone XR
Description: experimental drug
Study NCT03468374 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lymphoscintigraphy
Description: Nuclear Medicine diagnostic device using radioactive material
Study NCT03468374 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Single Photon Emission Tomography
Description: Nuclear Medicine diagnostic device using fusion technique between SPECT and CT
Study NCT04192799 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Direct admission
Description: Process of pediatric admission is through admission directly into the pediatric hospital medicine unit
Study NCT04192799 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ED admission
Description: Process of pediatric admission is through the emergency department
Study NCT05924451 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Immediate Loading
Description: Clinical and radiographic examination of the periimplant soft and hard tissue will be analysed by using gingival index, plaque index, and pocket depth immediately post operative.
Study NCT05924451 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Immediate Loading
Description: Clinical and radiographic examination of the periimplant soft and hard tissue will be analysed by using gingival index, plaque index, and pocket depth immediately post operative.
Study NCT03940586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letermovir oral granules
Description: Granules administered orally based on age, weight, and whether participant takes cyclosporin A as a concomitant medication.
Study NCT03940586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letermovir tablet
Description: Tablet administered orally based on age, weight, and whether participant takes cyclosporin A as a concomitant medication.
Study NCT03940586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letermovir intravenous
Description: Letermovir administered intravenously based on age, weight, and whether participant takes cyclosporin A as a concomitant medication.
Study NCT02808663 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: fecal calprotectin concentration
Study NCT02808663 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood collection
Study NCT01051999 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glutamine
Description: Oral glutamine powder
Study NCT01051999 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: L-alanine
Description: L-alanine oral powder
Study NCT04113538 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: Intraocular injection of 2 ml (40mg/ml)
Study NCT04113538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept
Description: Intraocular injection of 2 ml (40mg/ml)
Study NCT03715673 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: von willebrand antigen and activity
Description: Measuring von Willebrand antigen and activity (VWF: RCo and VWF: CB)
Study NCT01676311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huperzine A
Description: Huperzine A will be administered for 12 weeks as outlined in the Arm Description
Study NCT01676311 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Arm (blinded randomization) for Huperzine A Intervention
Study NCT04492007 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient-Reported Outcomes-Informed Symptom Management System (PRISMS)
Description: Participants will receive personalized self-care information and guidance based on their symptoms and signs of complications (e.g., skin infection, fatigue) from the web-based telehealth PRISMS program. They will also have access through this website a peer support online forum that is moderated by a research nurse as well as professional support through videoconferencing/telephone from the research nurse and also their healthcare providers at the hospital(s) if they experience moderate to severe symptoms and/or abnormal sign (e.g., body temperature is greater than 98.6 C
Study NCT04023318 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Lifestyle Intervention
Description: This program is grounded in data demonstrating the dysregulation across multiple domains and considerable life stressors experienced by this population. The central hypothesis is that by simultaneously ameliorating psychological dysregulation and directly targeting proinflammatory behaviors, ILI operates on multiple proposed mediators of poor treatment outcomes in this population, thereby enhancing treatment outcomes. As such, the overall framework emphasizes integration of self-regulation as it applies to both psychological functioning and weight control. Content will highlight the interconnectedness of mood, stress, eating and exercise behaviors, and risk for inflammation and disease. Each treatment session will present a combination of behavioral and psychological content, representing a truly integrated approach. Participants will meet for 75-minute group sessions weekly for months 1-2, followed by bi-weekly groups in months 3-4, for a total of 12 groups.
Study NCT01890694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Description: 15 mg once daily
Study NCT01890694 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 15 mg once daily
Study NCT01890694 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Hepatic Encephalopathy Assessment
Description: The Number connection test, Digit symbol test, Constructional apraxia, Inhibitory control test, Repeatable Battery for the Assessment of Neuropsychological Status will be administered on Days 1, 2, 4, 6, and 8; discharge day; Weeks 1-4 post-discharge; and Months 2-6 post-discharge.
Study NCT01890694 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hepatic Encephalopathy Assessment
Description: The Number connection test, Digit symbol test, Constructional apraxia, Inhibitory control test, Repeatable Battery for the Assessment of Neuropsychological Status will be administered on Days 1, 2, 4, 6, and 8; discharge day; Weeks 1-4 post-discharge; and Months 2-6 post-discharge.
Study NCT01890694 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Quality of Life Assessment
Description: The SF-36 and Liver Disease Questionnaire will be administered on Day 1, Discharge day, Weeks 1-4 post-discharge, and months 2-6 post-discharge
Study NCT05316207 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telenursing
Description: From the end of the first week after discharge to the end of the first month, patients were counseled over the phone during the home process. Complications were followed up.
Study NCT01890694 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quality of Life Assessment
Description: The SF-36 and Liver Disease Questionnaire will be administered on Day 1, Discharge day, Weeks 1-4 post-discharge, and months 2-6 post-discharge
Study NCT01890694 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Vital signs
Description: Vital signs (blood pressure, heart rate, respiration, temperature, weight, height) will be recorded at every visit.
Study NCT01890694 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vital signs
Description: Vital signs (blood pressure, heart rate, respiration, temperature, weight, height) will be recorded at every visit.
Study NCT00486785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alfuzosin
Description: Alfuzosin 10mg Once Daily for 24 weeks
Study NCT01890694 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Blood laboratory tests
Description: Blood laboratory tests (chemistry, hematology, liver function, urine electrolytes, renin, and copeptin) will be recorded at every visit.
Study NCT01890694 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood laboratory tests
Description: Blood laboratory tests (chemistry, hematology, liver function, urine electrolytes, renin, and copeptin) will be recorded at every visit.
Study NCT01890694 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Ascites Evaluation
Description: Ascites will be assessed at every visit.
Study NCT01890694 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ascites Evaluation
Description: Ascites will be assessed at every visit.
Study NCT01890694 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Edema
Description: Edema will be assessed at every visit.
Study NCT01890694 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Edema
Description: Edema will be assessed at every visit.
Study NCT03871569 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: bucco-dental teleexpertise
Description: A bucco-dental consultation remotely using telemedicine system
Study NCT01665573 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF-04457845
Description: Acquisition of conditioning Administration of drug Extinction of conditioning
Study NCT01665573 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PF-04457845
Description: Acquisition of conditioning Administration of drug Extinction of conditioning
Study NCT01665573 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Acquisition of conditioning Administration of placebo Extinction of conditioning
Study NCT01665573 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Acquisition of conditioning Administration of placebo Extinction of conditioning
Study NCT02174419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nalbuphine HCl ER tablets 90 mg BID
Description: nalbuphine HCl ER tablets 90 mg BID administered for 8 weeks
Study NCT02174419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nalbuphine HCl ER tablets 180 mg BID
Description: nalbuphine HCl ER tablets 180 mg BID administered for 8 weeks
Study NCT02174419 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablets BID
Description: Placebo tablets BID administered for 10 weeks